GCG and type 2 diabetes mellitus: To date, the metabolic therapy of T2DM is expanding beyond classic oral hypoglycaemic agents, such as insulin sensitisers and secretagogues, by incorporating modulation of the incretin system through glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) [17].